Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Kaplan Fox & Kilsheimer LLPKaplan Fox & Kilsheimer LLP Alerts Investors of Hims & Hers Health, Inc. (HIMS) to an Investigation of Potential Securities Law ViolationsKaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing...
- Kairos Pharma, Ltd.Kairos Pharma Announces 1-for-7 Reverse Stock SplitLOS ANGELES, August 21, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m.
- Philip Morris International Inc.FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific ReviewSTAMFORD, CT, August 21, 2026--Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S.
- Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct OfferingJupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering.
- Segal TrialsSegal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR StudyMIAMI LAKES, Fla., August 21, 2026--Segal Trials today announced its participation in the Phase 2 ZEPHYR clinical trial evaluating MapLight Therapeutics’ investigational muscarinic receptor-targeted therapy, ML-007C-MA, for the treatment of adults experiencing an acute exacerbation of schizophrenia.
- Allies of SkinAllies of Skin Celebrates the Launch of Peptint with an Exclusive Los Angeles Event Featuring Amber MarkThe Sound Lounge at Revolve at The Grove Unveiled the Grammy-Nominated Singer-Songwriter as the Face of the Brand's New Peptint Campaign — Allies of Skin, the results-driven skincare brand known for its supercharged clinical formulas, celebrated...
- Bay Area Lyme Ventures Invests in LymeLess Health to Accelerate AI-Powered Innovation for Lyme & Tick-Borne Disease PatientsInvestment supports launch of AI care companion, Ella, designed to help Lyme+ patients navigate diagnosis, treatment, and long-term disease management
- Palmetto Publishing Releases Vickie Marie Swafford's New Guide to Understanding and Preventing Teen SuicideDrawing on years of clinical experience with adolescent suicide patients, registered nurse Vickie Marie Swafford, MS, RN offers parents actionable strategies in her newly published book from Palmetto Publishing.
- Global Spatial Proteomics Market Size to Reach USD 400.10 Million by 2035 at 15.05% CAGR – SNS InsiderU.S. market to reach USD 156.90M and Europe USD 96.02M by 2035, driven by pharma R&D, biomarker development and multiplexed imaging.
- CharmHealthCharmHealth Introduces Ria, AI Solutions Advisor, to Speed Up Health IT Evaluation for Provider OrganizationsPLEASANTON, Calif., August 21, 2026--CharmHealth website visitors can start a conversation with AI solutions advisor Ria to run product demos, answer pricing, billing & setup questions.
- CureGeneCureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β AgonistCureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed in-house, in Australia. Subject enrollment is progressing smoothly. CG-0416 is designed...
- Azitra, Inc.Azitra, Inc. Regains Compliance with NYSE American Continued Listing StandardsAzitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced...